First COPD Patient Enrolled in Phase 4 Study of Yupelri vs. Spiriva
A first patient has been enrolled in a Phase 4 study of the effectiveness of Yupelri (revefenacin) against Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD). The respective safety of these two approved, once-daily COPD maintenance treatments will also be evaluated. Yupelri, developed…